Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regen Biopharma ( (RGBP) ) has shared an update.
On July 28, 2025, Regen Biopharma, Inc. entered into a securities purchase agreement with CFI Capital LLC, resulting in the issuance of a 6% convertible promissory note valued at $130,000. This agreement allows CFI to convert the note into common stock at a discounted rate, potentially impacting Regen Biopharma’s stock market activity and investor relations.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing innovative treatments and therapies. The company is involved in the research and development of regenerative medicine and immunotherapy solutions.
Average Trading Volume: 55,153
Technical Sentiment Signal: Sell
Current Market Cap: $1.58M
Find detailed analytics on RGBP stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money